Clinical trial NCT00787761: Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
Official title: Pre-administration of Rabbit Antithymocyte Globulin to Optimize Donor T-Cell Engraftment Following Reduced Intensity Allogeneic Peripheral Blood Progenitor Cell Transplantation From Matched-Related Donors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Myeloproliferative Disorders
Kidney Cancer
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Keywords: accelerated phase CML
blastic phase CML
Philadelphia chromosome positive CML
stage I CLL
stage II CLL
stage III CLL
stage IV CLL
stage I multiple myeloma
stage II multiple myeloma
stage III multiple myeloma
adult AML with 11q23 (MLL) abnormalities
adult CML in remission
adult ALL in remission
stage IV renal cell cancer
de novo MDS
previously treated MDS
secondary MDS
atypical CML, BCR-ABL negative
chronic myelomonocytic leukemia
MDS/myeloproliferative neoplasm, unclassifiable
primary myelofibrosis
chronic neutrophilic leukemia
recurrent adult Hodgkin lymphoma
clear cell renal cell carcinoma
adult AML with inv(16)(p13;q22)
adult AML with t(15;17)(q22;q12)
adult AML with t(16;16)(p13;q22)
adult AML with t(8;21)(q22;q22)
adult nasal type extranodal NK/T-cell lymphoma
AML/transient myeloproliferative disorder
Burkitt lymphoma
chronic phase CML
extranodal marginal zone B-cell lymphoma of mucosa tissue
nodal marginal zone B-cell lymphoma
stage III adult Burkitt lymphoma
stage IV adult Burkitt lymphoma
recurrent adult Burkitt lymphoma
stage III adult diffuse large cell lymphoma
stage III adult diffuse mixed cell lymphoma
recurrent adult diffuse large cell lymphoma
stage IV adult diffuse large cell lymphoma
stage IV adult diffuse mixed cell lymphoma
recurrent adult diffuse mixed cell lymphoma
stage III adult immunoblastic large cell lymphoma
stage IV adult immunoblastic large cell lymphoma
stage III adult lymphoblastic lymphoma
stage IV adult lymphoblastic lymphoma
recurrent adult immunoblastic large cell lymphoma
recurrent adult lymphoblastic lymphoma
recurrent grade 3 follicular lymphoma
stage III grade 3 follicular lymphoma
stage IV grade 3 follicular lymphoma
recurrent mantle cell lymphoma
stage III mantle cell lymphoma
stage IV mantle cell lymphoma
contiguous st II adult diffuse small cleaved cell lymphoma
noncontiguous st II diffuse small cleaved cell lymphoma
recurrent adult diffuse small cleaved cell lymphoma
stage III adult diffuse small cleaved cell lymphoma
stage IV adult diffuse small cleaved cell lymphoma
contiguous stage II grade 1 follicular lymphoma
contiguous stage II grade 2 follicular lymphoma
noncontiguous stage II grade 1 follicular lymphoma
noncontiguous stage II grade 2 follicular lymphoma
recurrent grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma
stage III grade 1 follicular lymphoma
stage III grade 2 follicular lymphoma
stage IV grade 1 follicular lymphoma
stage IV grade 2 follicular lymphoma
contiguous stage II marginal zone lymphoma
noncontiguous stage II marginal zone lymphoma
recurrent marginal zone lymphoma
stage III marginal zone lymphoma
stage IV marginal zone lymphoma
contiguous stage II small lymphocytic lymphoma
noncontiguous stage II small lymphocytic lymphoma
recurrent small lymphocytic lymphoma
stage III small lymphocytic lymphoma
stage IV small lymphocytic lymphoma
recurrent adult grade III lymphomatoid granulomatosis
relapsing chronic myelogenous leukemia
refractory chronic lymphocytic leukemia
splenic marginal zone lymphoma
Waldenstrom macroglobulinemia
recurrent adult T-cell leukemia/lymphoma
stage III adult T-cell leukemia/lymphoma
stage IV adult T-cell leukemia/lymphoma
anaplastic large cell lymphoma
angioimmunoblastic T-cell lymphoma
Lead sponsor: Northside Hospital, Inc.
Sponsor class: OTHER
Collaborators: name: Blood and Marrow Transplant Group of Georgia
First posted: 2008-11-10
Enrollment: 24
Sex: ALL
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving antithymocyte globulin before the transplant and tacrolimus and methotrexate after the transplant may stop this from happening.

PURPOSE: This phase II trial is studying how well giving antithymocyte globulin together with cyclophosphamide, busulfan, and fludarabine works in treating patients with hematological cancer or kidney cancer undergoing donor stem cell transplant.

Detailed description: OBJECTIVES:

* To assess the percentage of patients with hematological malignancies or renal cell carcinoma who achieve \> 90% donor T-cell chimerism at 30 days after treatment with reduced-intensity conditioning comprising low-dose anti-thymocyte globulin, low-dose cyclophosphamide, busulfan, and fludarabine phosphate followed by allogeneic peripheral blood progenitor cell transplantation from a matched related donor.
* To assess the incidence of severe (grade 3 or 4) acute graft-versus-host disease (GVHD) and extensive chronic GVHD in these patients.
* To assess whether this regimen is associated with reduced transplant-related toxicity and increased tolerability in these patients.
* To assess the overall safety of this conditioning regimen as measured by 6-month transplant-related mortality in these patients.
* To determine the efficacy of this regimen in inducing durable remissions in these patients.

OUTLINE:

* Reduced-intensity conditioning (RIC): Patients receive anti-thymocyte globulin IV over 4-6 hours on day -16 and over 6-8 hours on day -15, fludarabine phosphate IV over 30 minutes on days -7 to -3, busulfan IV over 3 hours on days -4 and -3, and cyclophosphamide IV over 1-2 hours on day -2.
* Transplantation: Patients undergo allogeneic peripheral blood progenitor cell transplantation on day 0.
* Graft-vs-host disease (GVHD) prophylaxis: Patients receive oral tacrolimus every 12 hours on days -1 to 90, followed by a taper until day 150. Patients also receive methotrexate IV on days 1, 3, and 6.

Blood samples are collected periodically for pharmacokinetic studies of anti-thymocyte globulin and PCR analysis for chimerism.

After completion of study therapy, patients are followed periodically for up to 3 years.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Histologically confirmed diagnosis of one of the following:

  * Chronic myeloid leukemia (CML)

    * Philadelphia chromosome (Ph)- and/or BCR-ABL-positive disease
    * In chronic or accelerated phase
    * Suboptimal response to imatinib mesylate (i.e., no hematologic complete response by 3 months, no major cytogenetic response by 6 months, or no complete cytogenetic response by 1 year)
    * CML in blastic transformation allowed provided patient achieved complete remission (CR) or second chronic phase after treatment with imatinib mesylate or chemotherapy
  * Chronic lymphocytic leukemia meeting one of the following criteria:

    * Rai stage III or IV disease
    * Rai stage I or II disease that failed standard therapy (i.e., disease is progressing after ≥ 1 course of standard therapy)
  * Non-Hodgkin lymphoma (NHL) meeting one of the following criteria:

    * Indolent NHL

      * Clinical stage III or IV disease or bulky stage II disease (i.e., ≥ one lymphoid mass \> 5 cm in ≥ one dimension)
      * Relapsed after primary therapy OR is refractory to therapy
    * Aggressive NHL

      * Is not considered curable with standard chemotherapy or autologous stem cell transplantation (i.e., relapsed after autologous stem cell transplantation)
      * Chemotherapy-responsive disease
  * Multiple myeloma

    * Durie-Salmon stage II or III disease

      * Durie Salmon stage I disease allowed provided β2 microglobulin level \> 3 mg/dL
  * Acute myeloid leukemia or acute lymphocytic leukemia

    * In CR (defined as \< 5% blasts in bone marrow and no circulating blasts) AND has any of the following poor prognostic features:

      * WBC \> 100,000/mm\^3 at presentation
      * In second or greater remission
      * Adverse-risk cytogenetics (i.e., Ph1-positive, 11q23 translocation, -5, -7, complex translocations, or other recognized adverse-risk cytogenetics)
  * Renal cell carcinoma

    * Stage IV disease
    * Clear cell morphology
  * Myelodysplastic syndromes

    * Bone marrow blasts ≤ 10% on last bone marrow biopsy prior to transplantation
  * Myeloproliferative disease

    * Anticipated life expectancy on conventional therapy \< 10 years
    * No uncomplicated essential thrombocythemia or primary polycythemia
  * Hodgkin lymphoma

    * Relapsed after ≥ 1 standard-dose chemotherapy regimen
    * Not considered curable by autologous stem cell transplantation
* No clinical evidence of active CNS involvement

  * Previously treated leptomeningeal disease allowed provided CSF cytology is negative at the time of assessment for transplantation
* Available 6/6 allele match (i.e., HLA-A, B, DRβ1)matched related donor

PATIENT CHARACTERISTICS:

* ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
* Bilirubin \< 3 times normal (unless abnormality due to malignancy)
* AST and ALT \< 3 times normal (unless abnormality due to malignancy)
* Creatinine ≤ 2.0 mg/dL
* LVEF ≥ 40% by MUGA or ECHO
* DLCO ≥ 40% of predicted
* FEV-1 ≥ 50% of predicted
* Not pregnant or nursing
* Fertile patients must use effective contraception
* Deemed to be an appropriate candidate for allogeneic SCT
* No evidence of myocardial infarction within the past 6 months
* No psychological or social condition that may interfere with study participation
* No serious uncontrolled localized or active systemic infection
* No second malignancy within the past 3 years except for completely excised nonmelanotic skin cancer or in situ carcinoma of the cervix
* No chronic inflammatory disorder requiring the continued use of glucocorticoids or other immunosuppressive medications
* No known HIV positivity
* No hypersensitivity to E. coli-derived proteins

Primary outcomes:
measure: Achievement of > 90% (Full) Donor Chimerism in the T-cell Lineage as Measured by PCR at Day 30 Post-transplantation
timeFrame: Day 30
Secondary outcomes:
measure: T-cell and Myeloid Chimerism at Days 90 Post-transplantation (>90% Chimerism)
timeFrame: Day 90
measure: T-cell and Myeloid Chimerism at Days 180 Post-transplantation (>90%)
timeFrame: 180 days
measure: Number of Patients Who Experience Severe (Grade 3 or 4) Acute Graft-versus-host Disease
timeFrame: Day 100
measure: Number of Patients Experiencing Extensive Chronic Graft Versus Host Disease (GVHD)
timeFrame: 2 years
measure: Non-relapse Mortality (NRM) at Day 180 Post-transplantation
timeFrame: Day 180
measure: Disease-free Survival (DFS) at 24 Months
timeFrame: 24 months
measure: Overall Survival (OS) at 24 Months
timeFrame: 24 months
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Blood and Marrow Transplant Group of Georgia
state: Georgia
Study officials:
affiliation: Blood and Marrow Transplant Group of Georgia
name: Asad Bashey, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rao SS, Peters SO, Crittenden RB, Stewart FM, Ramshaw HS, Quesenberry PJ. Stem cell transplantation in the normal nonmyeloablated host: relationship between cell dose, schedule, and engraftment. Exp Hematol. 1997 Feb;25(2):114-21.
citation: Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP, Leisenring W, Shulman H. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997 Apr 15;89(8):3048-54.
citation: Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15;89(12):4531-6.
citation: Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998 Feb 1;91(3):756-63.
citation: McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, Chauncey TR, Gooley TA, Hegenbart U, Nash RA, Radich J, Wagner JL, Minor S, Appelbaum FR, Bensinger WI, Bryant E, Flowers ME, Georges GE, Grumet FC, Kiem HP, Torok-Storb B, Yu C, Blume KG, Storb RF. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001 Jun 1;97(11):3390-400. doi: 10.1182/blood.v97.11.3390.
citation: Champlin R, Khouri I, Anderlini P, De Lima M, Hosing C, McMannis J, Molldrem J, Ueno N, Giralt S. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications. Oncology (Williston Park). 2003 Jan;17(1):94-100; discussion 103-7.
citation: Platzbecker U, Ehninger G, Schmitz N, Bornhauser M. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation in myeloid diseases. Ann Hematol. 2003 Aug;82(8):463-468. doi: 10.1007/s00277-003-0680-7. Epub 2003 Jun 21.
citation: Storb R. Non-myeloablative allogeneic transplantation -- state-of-the-art. Pediatr Transplant. 2004 Jun;8 Suppl 5:12-8. doi: 10.1111/j.1398-2265.2004.00189.x.